European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.
Female Urogenital Diseases and Pregnancy Complications
Decision date
28/10/2025
Enrollment target
8
Sites
France, Spain, Austria, Denmark
Condition studied
Faecal incontinence
Eligibility
Age group
65+ years, 18-64 years
Sex
Female
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.